Okyo Pharma Limited (OKYO.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 03/31
| 03-2020 | 03-2019 | 03-2018 | 03-2017 | 03-2016 | |
| Cash Flows From Operating Activities | |||||
| Depreciation Amortization | 6 | 0 | N/A | N/A | N/A |
| Accounts receivable | -140 | -131 | 0 | 33 | 75 |
| Accounts payable and accrued liabilities | 264 | N/A | N/A | N/A | N/A |
| Other Working Capital | 161 | 177 | -116 | 135 | 109 |
| Other Operating Activity | -1,609 | -2,036 | -1,280 | -730 | -835 |
| Operating Cash Flow | $-1,318 | $-1,990 | $-1,395 | $-561 | $-651 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | 0 | -1 | N/A | -2 | 70 |
| Other Investing Activity | 0 | 0 | 0 | -374 | -406 |
| Investing Cash Flow | $0 | $-1 | $N/A | $-375 | $-335 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | N/A | N/A | N/A | 4 | 12 |
| Debt Repayment | -6 | N/A | N/A | N/A | N/A |
| Common Stock Issued | 964 | N/A | N/A | N/A | N/A |
| Financing Cash Flow | $958 | $N/A | $N/A | $4 | $12 |
| Exchange Rate Effect | N/A | N/A | 0 | 405 | -172 |
| Beginning Cash Position | 595 | 2,619 | 4,209 | 4,453 | 6,274 |
| End Cash Position | 235 | 628 | 2,814 | 3,925 | 5,129 |
| Net Cash Flow | $-360 | $-1,991 | $-1,395 | $-932 | $-974 |
| Free Cash Flow | |||||
| Operating Cash Flow | -1,318 | -1,990 | -1,395 | -561 | -651 |
| Capital Expenditure | N/A | -1 | N/A | -375 | -406 |
| Free Cash Flow | -1,318 | -1,991 | -1,395 | -937 | -1,057 |